【レポートの概要（一部）】
01. Executive Summary
02.List of Abbreviations
03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05.Introduction
06.Disease Overview
06.1 Understanding the Disease
06.2 Pathophysiology
06.3 Epidemiology
06.4 Diagnosis
06.5 Staging
06.5.1 Staging: Colon Cancer
06.5.2 Staging: Rectal Cancer
06.6 Management
06.7 Economic Burden
07.Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.2.1 Colorectal Cancer Drugs Market in US
07.2.2 Colorectal Cancer Drugs Market in Germany
07.2.3 Colorectal Cancer Drugs Market in Spain
07.2.4 Colorectal Cancer Drugs Market in Japan
07.2.5 Colorectal Cancer Drugs Market in China
07.3 Five Forces Analysis
08.Market Segmentation by Type of Molecules
08.1 Small molecules
08.2 Biologics
09.Market Segmentation by Route of Administration
09.1 Oral
09.2 Parenteral
10.Geographical Segmentation
10.1 Colorectal Cancer Drugs Market in Americas
10.1.1 Market Size and Forecast
10.2 Colorectal Cancer Drugs Market in EMEA
10.2.1 Market Size and Forecast
10.3 Colorectal Cancer Drugs Market in APAC
10.3.1 Market Size and Forecast
11.Key Leading Countries
11.1 US
11.2 Japan
11.3 Germany
11.4 Spain
11.5 China
12.Buying Criteria
13.Market Growth Drivers
14.Drivers and their Impact
15.Market Challenges
16.Impact of Drivers and Challenges
17.Market Trends
18.Trends and their Impact
19.Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 Competitive Assessment of Top Drugs for Colorectal Cancer
19.2.2 F. Hoffmann-La Roche
19.2.3 Merck Serono
19.2.4 Bristol-Myers Squibb
19.2.5 Amgen
19.2.6 Sanofi
19.2.7 Bayer
19.3 Other and Future Prominent Vendors
20.Key Takeaways
21.Key Vendor Analysis
21.1 Amgen
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2013
21.1.4 Product Portfolio by Revenue 2013
21.1.5 Business Segmentation by Revenue 2012 and 2013
21.1.6 Geographical Segmentation by Revenue 2013
21.1.7 Business Strategy
21.1.8 Recent Developments
21.1.9 SWOT Analysis
21.2 Bayer
21.2.1 Key facts
21.2.2 Business overview
21.2.3 Business segmentation by revenue 2014
21.2.4 Business segmentation by revenue 2013 and 2014
21.2.5 Geographical segmentation by revenue 2014
21.2.6 Business strategy
21.2.7 Recent developments
21.2.8 SWOT analysis
21.3 Bristol-Myers Squibb Co.
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Key Product Offerings
21.3.4 Revenue by Geography
21.3.5 Business Strategy
21.3.6 Key Information
21.3.7 SWOT Analysis
21.4 F. Hoffmann-La Roche Ltd.
21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Business Segmentation
21.4.4 Business Segmentation by Revenue 2012 and 2013
21.4.5 Sales by Geography
21.4.6 Business Strategy
21.4.7 Key Information
21.4.8 SWOT Analysis
21.5 Merck Serono
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Geographical Segmentation by Revenue 2013
21.5.4 Business Strategy
21.5.5 Recent Developments
21.5.6 SWOT Analysis
21.6 Sanofi SA
21.6.1 Key Facts
21.6.2 Business Description
21.6.3 Business Segmentation
21.6.4 Revenue by Business Segmentation
21.6.5 Revenue Comparison 2012 and 2013
21.6.6 Sales by Geography
21.6.7 Business Strategy
21.6.8 Key Developments
21.6.9 SWOT Analysis
22.Other Reports in this Series
[List of Exhibits]
Exhibit 1: Market Research Methodology
Exhibit 2: Drivers and Challenges of the Global Colorectal Cancer Drugs Market
Exhibit 3: Diagnosis of Colorectal Cancer
Exhibit 4: Management of Colorectal Cancer
Exhibit 5: A Snapshot of the Economic Burden of the Global Colorectal Cancer Drugs Market
Exhibit 6: Snapshot of the Global Colorectal Cancer Drugs Market
Exhibit 7: Global Colorectal Cancer Drugs Market 2014-2019 ($ millions)
Exhibit 8: Colorectal Cancer Drugs Market in US 2014-2019 ($ millions)
Exhibit 9: Colorectal Cancer Drugs Market in Germany 2014-2019 ($ millions)
Exhibit 10: Colorectal Cancer Drugs Market in Spain 2014-2019 ($ millions)
Exhibit 11: Colorectal Cancer Drugs Market in Japan 2014-2019 ($ millions)
Exhibit 12: Colorectal Cancer Drugs Market in China 2014-2019 ($ millions)
Exhibit 13: Segmentation of Global Colorectal Cancer Drugs Market by Type of Molecules
Exhibit 14: Segmentation of Global Colorectal Cancer Drugs Market by Type of Molecules, 2014
Exhibit 15: Segmentation of Global Colorectal Cancer Drugs Market by Route of Administration
Exhibit 16: Segmentation of Global Colorectal Cancer Drugs Market by Route of Administration, 2014
Exhibit 17: Global Colorectal Cancer Drugs Market by Geographical Segmentation 2014
Exhibit 18: Colorectal Cancer Drugs Market in Americas 2014-2019 ($ millions)
Exhibit 19: Colorectal Cancer Drugs Market in EMEA 2014-2019 ($ millions)
Exhibit 20: Colorectal Cancer Drugs Market in APAC 2014-2019 ($ millions)
Exhibit 21:
Exhibit 22: Drivers of the Global Colorectal Cancer Drugs Market
Exhibit 23: Challenges of the Global Colorectal Cancer Drugs Market
Exhibit 24: Trends of the Global Colorectal Cancer Drugs Market
Exhibit 25: YoY Growth Rate of the Major Colorectal Cancer Drugs 2010-2014 ($ millions)
Exhibit 26: F. Hoffmann-La Roche: Product Portfolio
Exhibit 27: Avastin: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
Exhibit 28: Avastin: Region-wise Revenues 2010-2014 ($ millions)
Exhibit 29: YoY Revenues and Growth Rate of Avastin in the US 2010-2014 ($ millions)
Exhibit 30: YoY Revenues and Growth Rate of Avastin in Europe 2010-2014 ($ millions)
Exhibit 31: YoY Revenues and Growth Rate of Avastin in Japan 2010-2014 ($ millions)
Exhibit 32: YoY International Revenues and Growth Rate of Avastin 2010-2014 (Except US, Europe, Japan) ($ millions)
Exhibit 33: Xeloda: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
Exhibit 34: Xeloda: Region-wise Revenues 2010-2014 ($ millions)
Exhibit 35: YoY Revenues and Growth Rate of Xeloda in the US ($ millions)
Exhibit 36: YoY Revenues and Growth Rate of Xeloda in Europe 2010-2014 ($ millions)
Exhibit 37: YoY Revenues and Growth Rate of Xeloda in Japan 2010-2014 ($ millions)
Exhibit 38: YoY International Revenues and Growth Rate of Xeloda (Except US, Europe, Japan) ($ millions)
Exhibit 39: Merck Serono: Product Portfolio
Exhibit 40: Erbitux: Revenue and YoY Growth Rate except US and Canada 2010-2014 ($ millions)
Exhibit 41: Erbitux: Region-wise Revenues 2012-2014 ($ millions)
Exhibit 42: Erbitux: Revenue and YoY Growth Rate in Europe 2012-2014 ($ millions)
Exhibit 43: Erbitux: Revenue and YoY Growth Rate in Emerging Markets 2012-2014 ($ millions)
Exhibit 44: Erbitux: Revenue and YoY Growth Rate in ROW 2012-2014 ($ millions)
Exhibit 45: Bristol-Myers Squibb: Product Portfolio
Exhibit 46: Erbitux: Revenue and YoY Growth Rate in US and Canada 2010-2014 ($ millions)
Exhibit 47: Amgen: Product Portfolio
Exhibit 50: Vectibix: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
Exhibit 51: Vectibix: Region-wise Revenues 2010-2014 ($ millions)
Exhibit 52: Sanofi: Product Portfolio
Exhibit 53: Eloxatin: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
Exhibit 54: Eloxatin: Region-wise Revenues 2010-2014 ($ millions)
Exhibit 55: YoY Revenues and Growth Rate of Eloxatin in the US ($ millions)
Exhibit 56: YoY Revenues and Growth Rate of Eloxatin in Europe ($ millions)
Exhibit 57: YoY Revenues and Growth Rate of Eloxatin in Emerging Markets ($ millions)
Exhibit 58: YoY Revenues and Growth Rate of Eloxatin in ROW 2010-2014 ($ millions)
Exhibit 59: Zaltrap: Global Revenue and YoY Growth Rate 2012-2014 ($ millions)
Exhibit 60: Zaltrap: Region-wise Revenue 2013-2014 ($ millions)
Exhibit 61: Bayer: Product Portfolio
Exhibit 62: Stivarga: Global Revenue and YoY Growth Rate 2012-2014 ($ millions)
Exhibit 63: Key Takeaways: Global Colorectal Cancer Drugs Market 2015-2019
Exhibit 64: Amgen: Business Segmentation by Revenue 2013
Exhibit 65: Amgen: Product Portfolio by Revenue 2013
Exhibit 66: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 67: Amgen: Geographical Segmentation by Revenue 2013
Exhibit 68: Bayer: Business segmentation by revenue 2014
Exhibit 69: Bayer: Business segmentation by revenue 2013 and 2014 (US$ billion)
Exhibit 70: Bayer: Geographical segmentation by revenue 2014
Exhibit 71: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 72: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
Exhibit 73: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 74: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 75: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 76: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 77: Merck Serono: Geographical Segmentation by Revenue 2013
Exhibit 78: Sanofi SA: Business Segmentation
Exhibit 79: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 80: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 81: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
【レポート販売概要】
■ タイトル：大腸癌治療薬の世界市場2015-2019■ 英文：Global Colorectal Cancer Drugs Market 2015-2019
■ 発行日：2015年6月17日
■ 調査会社：Technavio
■ 商品コード：IRTNTR6118
■ 調査対象地域：グローバル
- 世界の分数馬力モーター（小形電動機）市場About Fractional Horsepower Motors An electric motor is a device that converts electric energy into mechanical motion. There are two types of electric motors based on their power classification: fractional horsepower motors and integral horsepower motors. Fractional horsepower motors are those that have an output power of less than 1 HP. These motors are mainly used in Home Appliance, HVAC, Water …
- 坑井仕上げ装置及びサービスの世界市場：パッカー、出砂対策ツール、多段階破砕ツール、ライナーハンガー、スマート坑井、安全弁This report estimates the completion equipment and services market size in terms of $million. This has been broken down into component regions and further split into countries. Completion equipment and services are required to complete the drilling process of an oil & gas well to commence production. The ever-increasing exploration & production activities across the globe and new areas of unconven …
- 世界の軍用回転翼航空機の市場動向2013-2023：競合環境及び戦略的インサイトThe report provides a detailed analysis of the competitive landscape of the Military Rotorcraft market. It provides an overview of key Military Rotorcraft companies catering to the Military Rotorcraft sector, together with insights such as key alliances, strategic initiatives and a brief financial analysis. The global rotorcraft industry is highly concentrated with the majority of the market captu …
- 膝インプラントの世界市場分析：手順別（全体、部分、膝関節再置換術）、コンポーネント別（固定ベアリング、可動ベアリングインプラント）、セグメント予測The global knee implant market was valued at USD 8.8 billion in 2015 and is expected to reach a value of USD 12.4 billion by 2024. This growth is majorly attributed to growing elderly population and surging prevalence of chronic rheumatic conditions such as osteoarthritis, rheumatoid arthritis, and post-traumatic arthritis. Primary factors that lead to the occurrence of arthritis are aging, physic …
- 遠隔電子ユニット（REU）の世界市場予測（～2022年）：操縦面、ランディングギ、燃料システム、防氷システム“The remote electronic unit market is projected to grow at a CAGR of 12.88% from 2017 to 2022”The remote electronic unit market is projected to grow from USD 2.78 billion in 2017 to USD 5.10 billion by 2022, at a CAGR of 12.88% from 2017 to 2022. Advancements in fly-by-wire and electric actuation systems technologies, miniaturization of remote electronic units in the aerospace industry, and increa …
- 環境修復の世界市場予測：バイオレメディエーション、ポンプ＆化学処理、土壌蒸気抽出法、熱処理、土壌洗浄The environmental remediation market is expected to be worth USD 123.13 Billion by 2022, at a CAGR of 7.62% between 2016 and 2022. It is widely used in the oil and gas and mining and forestry applications. Environmental remediation is one of the environmental services perceived as a long-term strategic solution for environmental pollution control by removing the contamination from soil and groundw …
- グローバルにおける嚢胞性線維症（CF症）治療薬市場：市場機会分析OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2018 - Event-Driven Update Summary Cystic Fibrosis (CF) is an autosomal recessive disease characterized by the secretion of thick, sticky mucus which clogs the lungs and leads to life-threatening lung infections; and obstructs pancreatic enzyme secretions that are essential for the body to break down and absorb nutrients. …
- データセンターセキュリティの世界市場分析：用途別（金融サービス、IT･通信、政府、教育、ヘルスケア、メディア･エンターテイメント）、サービス別（コンサルティング、統合･展開、マネージドサービス）、ソリューション別（論理セキュリティ、物理セキュリティ）、地域別、セグメント予測The data center security market is expected to reach USD 15.49 billion by 2024, according to a new report by Grand View Research, Inc. Data center security encompasses all the measures taken to encapsulate the data center environment and protect it from intrusion. It needs to be safeguarded against attacks and manipulation at both physical and logical level, subsequently creating a need for a cumu …
- 高等教育ソリューションの世界市場2016-2020About Higher Education Nations have begun to understand the need to retain their competitive edge by developing and sustaining a skilled workforce. In this context, higher education plays a critical role in the innovation and development of efficient human capital, which in turn will play a crucial role in the success and sustainability of the economy. Higher education institutes have been continu …
- 頭頚部癌検査の世界市場：画像診断、内視鏡検査、歯科検査、生検About head and neck cancer Various types of malignant tumors grown in and around head and neck are collectively known as head and neck cancers. Most head and neck cancers usually begin in the squamous cells that line the moist mucosal surfaces inside the mouth, throat, and nose. This is often identified as squamous cell carcinoma. The cancers start in the oral cavity, nasal cavity, larynx, salivar …
- 世界の金融産業における静脈認証（生体認証）市場：指静脈認証、手のひら静脈認証About vein recognition biometrics in BFSI sector The demand for highly reliable and accessible personal authentication and identification systems is increasing in the BFSI sector because of the growing instances of security vulnerabilities and transactional fraudulent in this sector. Biometrics is a suitable and reliable solution as it is based on the behavioral and physiological characteristics o …
- データセンター用IT装置の世界市場：サーバ、ストレージ、ネットワーク製品About data center IT equipment Enterprises build a data center to house IT equipment such as servers, storage, and network infrastructures. A data center also includes virtual and security appliances for business operational purposes. Most of the modern IT infrastructures such as converged infrastructure offered by vendors are designed to support any business environments. However, data center env …
- 地中熱ヒートポンプの世界市場2017-2021ABSTRACTAbout Geothermal Heat Pump Geothermal heat pump systems consist of the heat pump unit, the ground heat exchanger, and the air delivery system (ductwork). The heat exchanger has a system of pipes called a loop, which is buried in the ground near the building. Fluid will circulate within the heat exchanger system. The pump exchanger either takes the heat from the building and transfers it to …
- LTE加入者、導入、スペクトラム、インフラ契約データベース（LTE Subscriptions, Deployments, Spectrum and Infrastructure Contracts Database Q1’2012 database）Driven by the growing demand for mobile broadband access, LTE adoption has considerably gained momentum throughout the globe with over 49 commercial deployments. Driven by these early launches global LTE subscriptions reached 6.4 Million at the end of Q4’2011. From an operator viewpoint Verizon Wireless (U.S) is leading the market with a 64 % market share thanks to its tremendous coverage footprin …
- BYOD及び企業におけるウェアラブル技術The line between consumer and business technology has gotten increasingly blurry during the past decade. Consumer devices are almost indistinguishable from enterprise gear. But the gap between software and applications in each category is far wider. However, wearable computing is distinct from the first iteration of BYOD. The enterprise sector will lead this time, and consumers may or may not foll …
